66.17

1.98% -1.34

After Hours: 66.17

Travere Therapeutics Inc (TVTX)

Overview News Price History Option Chain Financials Why TVTX Down? Discussions Forecast Stock Split

Travere Therapeutics Inc stock is traded at $66.17, with a volume of 1.15M. It is down -1.98% in the last 24 hours and up +9.90% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Previous Close:

$67.51

Open:

$67.76

24h Volume:

1.15M

Relative Volume:

0.68

Market Cap:

$6.24B

Revenue:

$536.20M

Net Income/Loss:

$-45.64M

P/E Ratio:

-123.73

EPS:

-0.5348

Net Cash Flow:

$-28.94M

1W Performance:

+1.36%

1M Performance:

+9.90%

6M Performance:

+132.42%

1Y Performance:

+164.68%

1-Day Range:

$66.11

$68.73

1-Week Range:

$63.48

$68.73

52-Week Range:

$22.05

$68.73

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name

Travere Therapeutics Inc

Sector

Healthcare (1069)

Industry

Biotechnology (595)

Phone

888-969-7879

Address

3611 VALLEY CENTRE DR, SAN DIEGO

Employee

497

Twitter

Next Earnings Date

2026-10-29

Latest SEC Filings

TVTX's Discussions on Twitter

Compare TVTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVTX Travere Therapeutics Inc	66.17	6.24B	536.20M	-45.64M	-28.94M	-0.5348
VRTX Vertex Pharmaceuticals Inc	515.44	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	781.49	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.39	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	143.97	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.77	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight
Oct-31-25	Reiterated	Citigroup	Buy
Jun-11-25	Reiterated	Citigroup	Buy
Jun-11-25	Resumed	H.C. Wainwright	Buy
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy
Nov-20-23	Initiated	Citigroup	Neutral
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform
Jul-21-23	Initiated	JP Morgan	Overweight
Jun-07-23	Resumed	Piper Sandler	Neutral
May-22-23	Initiated	TD Cowen	Outperform
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform
Dec-14-22	Initiated	Stifel	Hold
Dec-05-22	Initiated	Wells Fargo	Overweight
Sep-21-22	Initiated	Bryan Garnier	Sell
Jul-14-22	Resumed	Canaccord Genuity	Buy
Mar-31-22	Initiated	Piper Sandler	Overweight
Feb-28-22	Initiated	H.C. Wainwright	Buy
May-26-21	Downgrade	Wedbush	Outperform → Neutral

View All

Travere Therapeutics Inc Stock (TVTX) Latest News

Sep 11, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Sep 11, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Sep 11, 2026

Director at Travere Therapeutics (TVTX) sells 20,000 shares under preset trading plan - Stock Titan

Sep 11, 2026

Show Me The Money: Filspari Powers Travere Therapeutics' Growth - RTTNews

Sep 11, 2026

Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employees - Bitget

Sep 11, 2026

Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Australia

Sep 11, 2026

Sep 10, 2026

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits

Sep 10, 2026

Travere Therapeutics (NASDAQ: TVTX) director plans 2026 stock sale - Stock Titan

Sep 10, 2026

TVTX: FILSPARI's momentum and pipeline progress position the business for sustained growth - TradingView

Sep 10, 2026

Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com Canada

Sep 10, 2026

Travere Therapeutics stock hits 52-week high at 68.25 USD - Investing.com

Sep 10, 2026